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Abstract— Personalized therapy requires accurate and frequent 
monitoring of drugs metabolic response in living organisms 
during drug treatments. In case of high risk side effects, e.g. 
therapies with interfering anti-cancer molecules cocktails, direct 
monitoring of the patient’s drug metabolism is essential as the 
metabolic pathways efficacy is highly variable on a patient-by-
patient basis. Moreover, anti-cancer pharmacological treatments 
are often based on cocktails of different drugs. Currently, there 
are no fully mature biochip systems to monitor multi-panel drugs 
amount in blood or in serum. The aim of this paper is to 
investigate the complexity of multiple drugs detection for point-
of-care systems to be used in personalized therapy. Probes 
molecules for the biochip are the P450 enzymes as they have key 
role in drugs metabolism. Multiple drugs detection is carried out 
both by simulations and electrochemical experiments. Drugs 
specificity enhancement is investigated considering components 
decomposition of peak as registered in cyclic voltammetry 
acquisitions. This investigation has the aim to identify crucial 
aspect in VLSI design of fully-electronics biochip development in 
this field.  
I.  INTRODUCTION  
New frontiers in personalized therapy also envisage the 
development of new tools for fast, easy-to-use, low cost, and 
point-of-care analysis of drugs efficacy on the patients.  The 
demand for new tools arose because still most effective drug 
therapies for major diseases provide benefit only to a fraction 
of patients, typically in the 20 to 50% range [1]. One of the 
reasons relies on the patient’s genetic polymorphism. For 
example, polymorphism in cytochrome P450 2D6 phenotype 
[2] causes overdosing in “poor metabolizers” and under-
dosing in “ultrafast metabolizers”, and explains why 
approximately 7% of hospitalized patients have serious 
adverse drug reactions  [1]. Some of the commonly used drugs 
for hypertensions or anti-cancer treatments (e.g. metoprolol 
and tamoxifen) are metabolized by this cytochrome. 
Therefore, it is being increasingly recognized that any drug 
therapy needs to be personalized to the individual patient  [3, 
4]. The only available monitoring system in the present state-
of-the-art for personalized therapy is a check of the genetic 
predisposition of patients. In order to know the risk for sub-
therapeutic or toxic drug concentrations, a genetic test is done 
on alleles, which correspond to patient genetic predisposition 
for expressing the P450 proteins. For example, mutations 
causing nonfunctional alleles may lead to a complete deletion 
of the CYP2D6 gene. For this aim, a genetic test based on 
microarray has been introduced into the marked by Roche: the 
AmpliChip CYP450 [5]. It is the first FDA-cleared test for 
analysis of only CYP2D6 and CYP2C19, two genes in the 
cytochrome P450 system that can greatly influence drug 
metabolism. By testing patient’s genotyping using AmpliChip, 
the patient can be classified as poor, intermediate, extensive, 
or ultra-rapid metabolizer. This classification affects the actual 
amount of mean plasma concentration after a single drug dose, 
as demonstrated in the case of nortriptyline [6]. However, this 
chip can only “predict” the patient’s phenotype while human 
metabolism may vary on a daily basis. Thus, in order to 
individually optimize an ongoing drug therapy, it is required to 
know drug concentrations in the patient’s body at the moment 
of the pharmacological cure. It is a major weakness in the 
concept of personalized medicine that the current available 
tools cannot acquire this information on real-time basis. 
Therapeutic drug monitoring, i.e. quantification of drug 
concentrations after administration to see whether the desired 
concentration range has been reached, is available only in 
large clinical chemistry labs. These chemistry labs typically 
offer this service for 20 drugs, and specialized labs at 
universities may run routine methods for 50 drugs, but they 
provide the measurements with timing of days. 
A reliable point-of-care technology to monitor multiple 
drug compounds in patients for personalized treatments is still 
not present either into the market or into the scientific state-of-
the-arte. In this paper, we propose a new method for designing 
biochips to measure multiple drugs concentration in real-time. 
The proposed system is based on multi-panel cytochromes 
P450 and opens the possibility to contemporary multi-drugs 
detection directly in patients’ serum. Biosensors based on 
individual P450 proteins have already been proposed to 
develop novel drug screening tools [7, 8, 9]. Electrodes nano-
structuring has been shown to enhance P450 based sensitivity 
by using zirconium dioxide [10] as well as gold [11] nano-
particles, and carbon nanotubes [12]. However, the 
development of P450 based chip for multi- drugs screening 
meets serious drawbacks as each P450 cytochrome detects 
many drugs and different P450s may detect the same drug. 
Aim of the present research is to identify these drawbacks and 
propose possible biochip design to overcome them. 
II.  P450 BASED ARRAY SYSTEM 
A P450 based biochip array provides a very powerful tool 
for personalization of drug therapy because of the key role of 
this proteins family in the human metabolism [13]. This 
section describes the P450 cytochromes, some of the drug 
substrates, and P450-drug interactions from the point of view 
of electrochemical investigation.  
 
A. P450 Protein family 
Cytochrome P450 (also abbreviated with CYP, or CYP450) is 
a diverse super-family of heme-proteins found in Bacteria, 
Archaea and Eukaryotes [14]. Cytochromes P450 are involved 
in metabolism of a plethora of both exogenous and 
endogenous compounds. 
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P450-2B4 P450-3A4 P450-2C9 
Benzphetamine (BZ) - anti-obesity Cyclophosphamide (CP) - anti-cancer agent Torsemide (TM) - Diuretic 
7-pentoxyresorufin (PX) - anti-obesity Dextromethorphan (DX) - analgesic Diclofenac (DC) - anti-inflammations 
Aminopyrine (AP) - anti-inflammatory/analgesic Midazolam (MZ) - Anticonvulsant/sedative S-Warfarin (SW) - anti-coagulant 
Table 1: interaction map of the biochip probe molecules and the target molecules considered in this study. The probes are different proteins of the cytochromes 
P450 family while the targets are commonly used drugs for cardiovascular, antidepressant, or anti-cancer therapies. N means no interaction. 
 
Usually, they form part of multi-component electron transfer 
chains, called P450-containing systems. Most P450 can 
metabolize multiple substrates, and many can catalyze 
multiple reactions, which accounts for their central importance 
in metabolizing the potentially endless variety of endogenous 
and exogenous molecules.  
In drug metabolism, cytochrome P450 is probably the most 
important element of oxidative metabolism (also known as 
Phase I metabolism) in humans (metabolism in this context 
being the chemical modification or degradation of chemicals 
including drugs and endogenous compounds). Up to 57 genes 
and more than 59 pseudo-genes of the human genome encode 
18 families of cytochrome P450 and 43 subfamilies. Heme 
proteins cytochromes P450 are capable of metabolizing a vast 
number and variety of organic substrates, estimated to be in 
the region of 200,000 chemicals or more, and involving 
around 60 distinct classes of biotransformation reactions. 
Metabolism mediated by cytochrome P450 enzymes plays a 
key role in the development of new drugs and in individual 
drug therapy.  
P450 proteins are known to metabolize all the drugs. For 
example, the protein CYP2D6, formerly named debrisoquine 
hydroxylase, is involved in the oxidative metabolism of about 
25% of commonly prescribed drugs [15]. A high range of 
inter-individual and inter-ethnic variability characterizes the 
enzyme activity, mainly caused by genetic polymorphisms. 
These polymorphisms can result in 30- to 40-fold differences 
in substrate drugs clearance, resulting in concentrations 
outside the therapeutic range in some treated patients. As a 
consequence, such differences in CYP2D6 activity may lead 
not only to severe adverse effects in clinical therapy, e.g., in 
antidepressant therapy [16], but also to non-response to 
medications, such as no observable analgesic effect after low 
doses of codeine in poor metabolizers (PM) [17]. Starting 
from the first description of a polymorphism in debrisoquine 
hydroxylation [18] until today, more than 80 allelic variants 
have been described [19]. The CYP2D6 genotype has a major 
impact on enzymatic activity. Today genotyping may be 
performed by arrays such as the AmpliChip CYP450 Test [5], 
which identifies 20 CYP2D6 alleles and seven CYP2D6 
duplications. However, genotyping alone may not exactly 
predict a person’s phenotype. Moreover, the CYP2D6 activity 
is modified by certain environmental factors, e.g., infections 
and nutritional habits [20]. Therefore, to obtain a precise 
picture of a person’s actual enzymatic activity, adequate probe 
drugs have to be administered followed by consecutive 
measurements of their concentrations and those of CYP2D6-
dependent metabolites in body fluids [21].  
 
 
B. Drugs substrates 
As a prelude to any individualized drug therapy aimed at 
preventing lack of response to medication or adverse effects 
due to different levels of P450 activity, genotyping as well as 
phenotyping have to be considered. The integrated multi-panel 
bio-sensor array platform can play a strategic role in 
monitoring phenotypic drug metabolism. Different P450 
cytochromes have to be considered to develop a multi-panel 
detection of drugs content in human serum. The same P450 
isoform may detect different drug compounds while the same 
drug compound is detected by different isoforms. To 
investigate the cross correlation between P450 enzymes to be 
considered as probe molecules for point-of-care biochips and 
drugs for screening in personalized therapies, we will consider 
here three different cytochromes and their drugs substrates. The 
enzyme P450 in the isoform 2B4 detects benzphetamine (BZ), 
aminopyrine (AP) and 7-pentoxyresorufin (PX). The 
benzphetamine is an anoretic compound closely related to 
amphetamine. It is often used in anti-obesity therapy. The 
aminopyrine is a drug with analgesic, anti-inflammatory, and 
antipyretic properties. The 7-pentoxyresorufin is indicated for 
infections, hischemia, hypertrophy, obesity, etc. The isoform 
P450 3A4 detects cyclophosphamide (CP), dextromethorphan 
(DX) and midazolam (MZ). Cyclophosphamide is an anti-
cancer agent; dextromethorphan is an analgesic, while 
midazolam is a benzodiazepine derivative. It has powerful 
anxiolytic, amnestic, hypnotic, anticonvulsant, skeletal muscle 
relaxant and sedative properties. Finally, the isoform 2C9 
detects torsemide (TM), diclofenac (DC), and S-Warfarin 
(SW). They are used for cardiovascular, anti-inflammations, 
anti-coagulant therapies, respectively. S-Surfamide is also used 
as anti-arrhythmic in cardiovascular treatments. Table 1 
summarizes the P450/drugs interactions used in the present 
study. The indicated P450 enzymes may be used to 
functionalize different electrodes spots in order to develop a 
electrochemical Biochip for multiple drugs monitoring. 
 
C. CV Signature 
An electrical signature is required to investigate the P450-
drugs interactions and to consider them for point-of-care 
biochip in drugs screening and monitoring. In particular, when 
more than one drug compound interacts with a cytochromes 
P450 onto the biochip electrodes, the biochip have to register a 
clear electrical signatures. This signature enables us to identify 
the drugs and to estimate its amount in the presence of other 
compounds cross interacting with the same biochip spot. 
Figure 1 show a typical electrochemical current registered in 
case of multiple electrolytes voltammetry. 
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Fig. 1. Electrochemical signature of three well separated electrolyte 
components as registered in a Cyclic Voltammograms. 
As clearly shown by the picture, the current shape upon 
the scanned voltage may be analyzed by considering Gaussian 
components. In fact, the cyclic voltammogram show a current 
peak that corresponds to the electrochemical signal registered 
during the redox reaction catalyzed by the cytochrome onto the 
single drug. If more drugs are present into the sample, then the 
voltammogram presents more than one peak. Each peak 
accounts for the different drug contribution to the electrolyte. 
This multiple voltammogram’ features is what we will refer to 
as the “electrochemical signature” of the drug contributions. 
Any multi-panel biochip needs to have implemented cyclic 
voltammograms signature features extraction in order to 
improve the specificity of single drug detection.  
 
III. MATERIALS AND METHODS 
A. The Simulator 
It is well known that multiple electrolytes produce multiple 
peaks in the single Cyclic Voltammograms [22]. A similar 
situation is modeled by the following equation: 
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where the first term accounts for the charging current, and the 
following sum of Gaussian curves accounts for all the Faradic 
currents generated by P450 multiple interactions with different 
drugs. Faradic currents from detection of different enzyme’ 
substrates are simulated by considering the P450 peaks shift 
(shift in Vk) occurring in cyclic voltammograms when drugs are 
detected, while the charging current (ic(V)) were acquired in 
real experiments with physiological buffer (PBS) as electrolyte 
but in the absence of any cytochrome onto the working 
electrodes. This current was assumed as base-line for simulated 
voltammograms. Peaks corresponding to electrochemical drugs 
detection as registered in cyclic voltammetry are generated by 
Gaussian curves. The position of each individual Gaussian are 
selected by information obtained from literature or registered in 
voltammetric experiments. Peak areas (parameters Ak, and σk) 
are instead estimated considering typical peak features in real 
experiments and ratio of kinetic parameters of the simulated 
drugs. 
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Fig. 2. Simulated voltammogram of a P450 2C9 sensor during the 
contemporary detection of TM, DC, SW, three not well resolved drugs. 
 
B. The Sensors 
The sensors were fabricated by using commercially 
available screen-printed electrodes and by using different 
P450 proteins and, in some cases, carbon nanotubes, too. 
Carbon paste screen-printed electrodes were purchased from 
Dropsens (model DRP-110). The electrodes were made of a 
graphite working electrode (area, 13 mm2), a graphite counter 
electrode and an Ag/AgCl reference electrode. The total area 
of the cell is 22 mm2. Cytochrome P450 3A4 microsomes 
were purchased from Sigma-Aldrigh and used without 
modifications. CP and DX drug (from Sigma) were diluted in 
PBS 100mM pH 7.4 in aliquots of 50 nM, 5 M, 500 M, 50 
mM. Experiments were also carried out by using the 
cytochromes P450 2B4. In this case, the cytochrome was 
isolated and purified from the microsomal fraction of rabbit 
[27]. Cytochrome and benzphetamine (BZ) substrates were 
received from Russia. For both cytochromes, sensing 
electrodes were prepared by spreading P450 solution onto 
working electrode and incubating at 37°C overnight. In same 
cases, the effects of electrodes nano-structuring were also 
tested. Multi walled carbon nanotubes (MWCNT), diameter 
10 nm, length 1-2 µm, COOH content 5 %) were purchased in 
powder (95% purity) from DropSense (Spain), diluted in 
chloroform to the concentration of 1 mg/ml [7] and then 
sonicated for 20 minutes in order to break macro-aggregates. 
In case of nano-structuring, the working electrodes were 
prepared in a 3 steps procedure: 60 l of CNT solution were 
drop casted onto the working electrode and dried. Electrodes 
were then incubated in milliQ water overnight in order to 
hydrate the nanostructure. The day After the P450 solution 
were spread onto working electrode and incubated at 37°C 
overnight.  
In all the cases, the electrochemical response was 
investigated by cyclic voltammetry under aerobic conditions. 
Voltammograms were acquired by using a Versastat 3 
potentiostat (Princeton Applied Technologies). The electrode 
was covered with 100 l of PBS 100 mM at pH 7.4 or with the 
same volumes of PBS added to 1 l of drugs samples. The 
cyclic voltammograms were acquired with potential sweeps 
between -600 and +300 mV vs Ag/AgCl by using different 
scan rates ranging from 20 to 100 mV/sec.  
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Fig. 3. Zoom in the region of interest of the Simulated Voltammogram of P450 
2C9 sensor during the contemporary detection of TM, DC, SW. 
 
IV. SIMULATION RESULTS 
 
A. P450 2C9 – Multiple Drugs Detection 
Detection of different drug substrates are simulated by 
considering the P450 peak shift occurring in cyclic 
voltammograms when drugs are detected. In case of the 
cytochrome 2C9, peak positions of the three considered drugs 
are slightly different. They are -19, -41, -36 mV for TM, DC, 
and SW, respectively, in presence of oxygen [23]. Figure 3 
shows the cyclic voltammogram outlined by simulations. The 
three individual drugs contributions into voltammogram of 
Figure 2 are not as well resolved as those in Figure 1. This is 
due to the close proximity of the redox peaks of the three 
compounds when the redox is catalyzed by the cytochrome. 
Nevertheless, Figure 3 shows that the individual substrate 
contributions are clearly present under the voltammogram 
peak. These drugs followed similar Michaelis–Menten 
kinetics. In fact, the Km are 11.4 ± 0.1 and 6.8 ± 0.01 mM for 
TM and DC, and the Vmax are 11.5 ± 0.5 and 23.2 ± 0.01 
pmol/min/ for pmol of P450 [23], while the Km of SW is close 
to 6 mM [24]. Thus, for drugs concentration in similar range 
of the different drugs, the peak registered while acquiring a 
cyclic voltammogram on the biochip spot will present 
contribution from the three compounds. For example, in the 
simulation of Figure 3, the drug concentrations are 20, 20, and 
15 mM for TM, DC, SW, respectively. 
V. EXPERIMENTAL RESULTS 
A. P450 3A4 – Multiple Drugs Detection  
To validate the simulations, experiments were carried out with 
screen-printed carbon paste electrodes. Figure 4 shows the 
zoon in the region of interest of a cyclic voltammogram, 
acquired with a scan rate of 20 mV/sec, during 
contemporaneous detection of Cyclophosphamide (CP), and 
Dextromethorphan (DX). The signal was analyzed by 
considering the individual peak positions registered in similar 
experiments where only an individual drug was present at a 
time. The peak positions are -414.4 ± 0.1 mV and -421.5 ± 0.1 
mV for CP and DX. The drug concentrations during the 
experiment were equal to 400 mM for both the DX and CP.  
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Fig. 4. Zoom in the region of interest of the a Voltammogram acquired with 
P450 3A4 sensor during the contemporary detection of CP and DX drugs. 
 
The two drug compounds present Km in the same magnitude 
order. The Km and Vmax are 595 uM and 26.9 pmol/min/ for 
pmol of P450 for CP [25], while they are 268 uM 1.74 
pmol/min/for pmol of P450 for DX [26]. In fact, detection 
peaks registered in the voltammograms are well explained by 
fitting accounting for both the DX and CP contributions with a 
small chi square. In case of Figure 4, it is equal to 2.32. 
 
B. P450 2B4 – Single Drug Detection  
Results of these experiments are reported in Figures 5, and 6. 
Figure 5 summarize the BZ detection as registered in cyclic 
voltammograms while the Figure 6 presents the effect of 
electrodes nano-structuring in chronoamperometric 
experiments. The chronoamperometries were registered by 
applying a constant potential equal to -400 mV and registering 
the current upon the time in sample were an increasing amount 
of BZ was added in different steps.  Figure 5 clearly shows as 
the single component peak is growing up upon BZ 
concentration. Figure 6 shows the calibration curve acquired 
in cronoamperometry. These curves demonstrate that the drug 
detection is enhanced by using nano-structured biochip 
electrodes.  The gain is close to one order of magnitudes, as 
already registered by using P450 proteins and carbon 
nanotubes [12].  
VI. DISCUSSION 
The possibility to develop Fully-Electronics biochips for 
Label-Free DNA detection has been already demonstrated 
[28]. In this section, a discussion on the possibility to develop 
a fully-electronics biochip for multi-panel drugs detection will 
be carried out taking into account the results of the present 
study.  
A. Peaks Separation by Fitting 
The components decomposition of registered peaks in multi-
panel drugs detection is a hard task, as clearly demonstrated 
both by simulations (Figure 3) and by experiments (Figure 4). 
Figure 3 is obtained by considering drugs in close proximity as 
compounds concentrations: 20, 20, and 15 mM for TM, DC, 
SW, respectively. However, simulations have clearly shown 
that different drugs contributions are closely superposed each 
other even in case of different amount ratios. 
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Fig. 5. Voltammogram acquired with  P450 2B4 onto Multi Walled 
Carbon Nanotubes during the detection of Benzphetamine (BZ). 
 
On the other hands, signal-to-noise ratio in real experiments of 
multiple drugs detection has demonstrated that fittings 
considering actual positions of each individual drug 
components are possible (Figure 4). Fitting return us current 
value for the single drug contribution which does not 
correspond to calibrations curve as registered in single drug 
experiments (such as in Figure 6). This is because presence of 
more than one drug onto the biochip spots means lesser 
amount of probe proteins for the same drug as the probes 
surface is partially occupied by the other drugs. Therefore, a 
correct drugs detection calibration must accounts for a family 
of curves, each related to different amount of the co-detected 
drugs. 
 
B. Enzymes Kinetics 
Enzymes kinetics on different target drugs plays a crucial role 
in designing a multi-panel biochip. In fact, both simulations 
and experiments shown in this study are related to P450-
substrates kinetics which are close each other. In this case, 
different contributions to a voltammetric peak are quite 
equally distributed between the different detected drugs. 
Therefore, the same spot functionalized with the same P450 
have the chance to detect different drugs that are 
contemporary present in the same sample. However, a drug 
contribution may be hided by those of other drugs 
contemporary present in the same sample in case it has highly 
different kinetics. This is the case, for example, of tolbutamide 
(TB). This compound is detected by the cytochrome P450 2C9 
as well as torsemide (TM), diclofenac (DC), and S-Warfarin 
(SW). The Km are 11.4 and 6.8 mM for TM and DC [23], and 
it is equal to 6 mM for SW [24], while it is equal to 120 mM 
for TB [29]. The Km is defined as the molar concentration at 
which the enzymatic reaction reach half of the max velocity. 
Thus, higher Km means smaller enzymatic velocity. This is 
reflected by a smaller current in electrochemical detection. 
Current registered in cyclic voltammograms is neither trivially 
nor linearly related to Km. The above reported numbers 
suggest us that contribution from TB will be hidden in case of 
drugs cocktails also involving TM, DC, SW. 
  
Fig. 6. Currents acquired at fixed potential for different concentration of 
Benzphetamine (BZ) with or without Multi Walled Carbon Nanotubes 
 
C. Drug Identification 
Components separation in the voltammetric peaks is, thus, a 
crucial task of the biochip in case of multi-panel detection. 
Moreover, it cannot avoid considering extra information about 
the proposed sample. For example, data set shown in Figure 4 
should be explained in terms of both CP and DX drugs with a 
chi-square equal to 2.32. However, it also may be explained 
considering only contribution from a single drug. In that case, 
the fitting chi-square is higher in case of fitting with only CP 
(4.25) but close to the previous one in case of DX (2.27).  
Signal-to-noise ratio does not authorize us to consider actually 
different the two numbers from fitting with DX+CP and from 
only the DX contribution, but the two numbers are really very 
close each other. However, the two drugs kinetics are so close 
[23, 24] that the right fitting is that considering both DX and 
CP. Therefore, both the information of the combined presence 
of the two drugs into the sample and those related the drugs 
kinetics have to be considered before deciding which drugs are 
present once acquired by the single cyclic voltammogram.  
 
D. Software tools for  biochip design 
As we have seen, a biochip for point-of-care technology based 
on the enzymes family P450 should be a very powerful 
platform for personalization of drug therapy because of the 
key role of P450. However, different P450 isoforms may have 
the same drug compound as substrate and different drugs may 
be substrates of the same P450 protein. Proper strategies to 
develop P450 based biosensor arrays and to query each single 
array spot, while at the same time maintaining high reliability 
and low cost of experimentation is highly desired. A possible 
array design to immobilize P450s for sensing multiple drugs 
have to consider redundancy and multiple enzyme-substrate 
interactions. In our approach, the readout is based on selecting 
the combinations that can distinguish the targets. This 
selection can be achieved by solving a covering problem[30]. 
An example is shown in Table 1 where a set of drugs {BZ; 
PX; AP; CP; DX; MZ; TM; DC; SW} is mapped into the 
cytochromes set {2B4; 2C9 ; 3A4}. A bit more complicated 
example is shown in Figure 7a. In Figure 7b, the e5, e9, e8 and 
e10 are the minimum number of probes. 
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Figure 7: A set cover representation of P450 based biochip design. In Figure a), the bounded boxes correspond to substrates and the disks to interacting enzymes. 
In Figure b), a subset of enzymes selected by the software that will be used to distinguish all the considered drug components in a mixture. 
 
A simple spot query at fixed potential like those in Figure 6 
is proposed for the following pairs {e5, s1}, {e8, s2}, {e9, s3}, 
{e10, s4}. A bit more complicated dynamical spot query like 
those in Figures 3 and 4 and further signal analysis for peaks 
separation is proposed to distinguish {e5, s4, s1}, {e9, s4, s3} 
and {e8, s4, s2} by voltammograms signature. If s4 is found 
to be absent in the mixture (absence of signal on e10) then 
the signal on probes e5, e9 and e8 is enough to prove the 
presence of s1, s3 and s2 respectively without using the 
signature information, and quantification may be done with 
calibration curves like one in Figure 4. If e10 probe detects 
the presence of s4 the software dynamically guides the 
sensor to make a scan for second potential range as defined 
by voltammogram signature to distinguish between {s4, s1}, 
{s4, s3} and {s4, s2}. Algorithms based on irredundant cover 
computation can be used to add this kind of artificial 
intelligence to the biosensor chip array. 
VII. CONCLUSIONS 
In the present paper we investigated a multi-panel 
technology that may provide real-time information on multi-
drugs metabolism. Such a system can enable early 
identification of drug candidates. Moreover, it may provide 
innovative solution for biochip for pharmacokinetic studies 
in animals and humans by shortening the typically 1-2 
months now available with current methods (e.g., LC-
MS/MS). Because some of the studies conducted are 
sequential, an optimal use of such a multi-panel biochip may 
accelerate drug development by several months, and it will 
save costs for analytics by an order of magnitude of 1 M. 
The potential socio-economical relevance of the biochip 
systems here proposed is huge for the worldwide society in 
order to improve the quality of life of the patients, in order 
to decrease the medical care costs, in order to shorten the 
time-to-market for drug producers, and in order to increase 
enormously the diagnostic market. However, this study has 
clearly outlined the bottleneck and drawbacks that one could 
face while developing such a biochip. A fully-electronics 
biochip for multi-panel drugs detection implementing 
enough intelligence to account for these problems is 
currently under investigation in our lab in order to verify the 
possibility to overcome all the drawbacks.  
ACKNOWLEDGMENT  
S.C. thanks Uwe Furh for useful discussions on personalized 
therapies and electrochemistry of P450. Victoria 
Shumyantseva, from Russian Academy of Biomedical 
Science, is acknowledged for supplying P450 2B4 and 
Benzphetamine. The research is financially supported by the 
EPFL - Integrated Center SI. 
REFERENCES 
[1]  J. Lazarou, B.H. Pomeranz, Corey P.N, JAMA.279 (1998)1200-5 
[2]  D. Frank et al., Eur J Clin Pharmacol (2007) 63:321–333 
[3]  S. T. Turner; et al.,  Hypertension.50 (2007)1-5; 
[4] A.K. Daly  Curr Opin Drug Discov Devel.10 (2007) 29-36 
[5]  http://www.amplichip.us/ 
[6]  Jiunn H. Lin, Current Drug Metabolism 8 (2007) 109-136 
[7]  S. Joseph, et al., Biochemical Pharmacology,. 65 (2003) 1817-1826. 
[8]  S. Liu, et al., Analytical Biochemistry 375 (2008) 209-216. 
[9]  E. Iwuoha, et al., IET Nanobiotechnology, 1 (2007) 62-67 
[10]  L. Peng, et al., Electroanalysis, 20 (2008) 803-807.  
[11]  V. Shumyantseva, et al., Biosensors & Bioelectronics, 21 (2005) 217-
222 
[12]  S. Carrara, et al., Biosensors and Bioelectronics, 24(2008) 148-150. 
[13]  Murray M & Petrovic N. Curr Opin Mol Ther. 8 (2006) 480-6 
[14]  Danielson P Curr Drug Metab 3 (2002)  561-97 
[15]  Bertz RJ, Granneman GR, Clin Pharmacokinet 32(1997) 210–258 
[16]  Kirchheiner J, et al. Mol Psychiatry 9 (2004) 442–473 
[17]  Gasche Y, N Engl J Med 351(2004) 2827–2831 
[18]  Mahgoub A, et al. Lancet 2(1977) 584–586 
[19]  Zanger UM, Naunyn-Schmiedeberg’s Arch Pharmacol, 369(2004) 
23–37 
[20]  Bertilsson L, Br J Clin Pharmacol 53(2002) 111–122 
[21]  U. Fuhr et al., Clin Pharmacol Ther 81(2007) 270-83 
[22] A.J. Bard, L.R. Faulkner, Electrochemical Methods, 2nd ed., N.Y. 
2001, pag 244. 
[23]  D.L. Johnson, et al., Biochemical Pharmacology, 69, (2005) 1533-
1541 
[24]  Haining RL.,Biochemistry; 38, (1999) 3285–92. 
[25]  Song Ren, et al., Cancer Research 7 (1997) 4229-4235 
[26]  Yi Wang et al., Biopharm. Drug Dispos. 20 (1999) 341–346 
[27]  V.V. Shumyantseva, et al., J. of Inorg. Biochemistry, 101,2007, 859-
865 
[28]  C. Stagni, et al., IEEE Sensor Journal  7 (2007) 577-585 
[29]  Miners JO, et al., Methods Enzymol 272(1996), 139–45 
[30] De Micheli G., Synthesis and Optimization of digital circuits, 
McGraw-Hill, 1994 
Authorized licensed use limited to: Giovanni De Micheli. Downloaded on August 13,2010 at 06:34:18 UTC from IEEE Xplore.  Restrictions apply. 
